Bentham Science Newsletter

Bentham Science News Roundup

Impact Factor Updates

Thirty-six Bentham Science journals have recorded higher impact factors for 2025. Current Neuropharmacology retains the top position with an improved Impact Factor of 6.1. Learn more from our press release here.

Open Access Collaborations

Bentham Science Expands Global Open Access Network with New Agreements and R&P Trials

Bentham Science, in its endeavor to support Open Access scholarly publishing and readership, has signed Open Access Collaborations and offered Read and Publish Trial across Europe, Asia, Australia, and the Americas. Notable updates include Read and Publish agreements offering 100% waiver on the listed Article Processing Charges (APC) for researchers from Oxford University (UK), Monash University (Australia and Malaysia), the Chinese Academy of Medical Sciences, The State University of Campinas (UniCamp) in Brazil, and many universities in Italy, Spain, and Türkiye. The Mount Sinai Health System (USA) has also signed an Open Access publishing and reading subscription with Bentham Science.

Concurrently, the publisher has launched several time-limited Read and Publish trials spanning hundreds of institutions across South Korea, Hungary, the Czech Republic, and Slovakia to bolster global research accessibility and evaluation.

Call for Papers - New Journals

Bentham Science is launching new journals.

Wireless and Communication Letters

Editor-in-Chief: Nasimuddin

Wireless and Communication Letters publishes high-quality, short-length original research articles on advances in the state of the art of wireless and communication systems. All aspects of recent advancements in theoretical and practical contributions, such as new techniques, system designs, concepts, analysis, experiment systems, prototypes, and applications, are encouraged. Learn more about the journal here.

Researchers can avail free Open Access publishing in the journal by submitting their article before December 31, 2026. Submit your paper here.

Glucolipid Metabolic Disorders

Editor-in-Chief: Yongsheng Li

Glucolipid Metabolic Disorders is an international, peer-reviewed, multi-disciplinary journal for physicians, clinicians, and scientists that publishes original research, guidelines, reviews, and commentaries on glucose and lipid metabolic disorders and their pathological processes, alongside the therapeutics designed to treat them. Learn more about the journal here.

Researchers can avail free Open Access publishing in the journal by submitting their article before December 31, 2026. Submit your paper here.

Gene Editing Technologies

Editor-in-Chief: Atta-ur-Rahman, FRS

Gene Editing Technologies is an international, peer-reviewed journal publishing full-length and mini-reviews, original research, and guest-edited thematic issues dedicated to the science and application of gene editing across biology and medicine. Learn more about the journal here.

Researchers can avail free Open Access publishing in the journal by submitting their article before December 31, 2026. Submit your paper here.

Journal Updates and Offers

Discounted Open Access Publishing:

Researchers can avail discounts on Open Access publishing in Combinatorial Chemistry & High Throughput Screening till September 30, 2026.

Avail Complementary Open Access Publishing in these journals:

Current Artificial Intelligence (Formerly the Chinese Journal of Artificial Intelligence) till October 31, 2026.

Wireless and Communication Letters till December 31, 2026.

Gene Editing Technologies till December 31, 2026.

Glucolipid Metabolic Disorders till December 31, 2026.

Expanded Continuous Publication Model

Several Bentham Science Journals like Current Diabetes Reviews and Anti-Infective Agents have adopted the Continuous Publication (CP) model enabling accepted articles to be published online immediately after production and formatting are completed. We are expanding the CP model to more journals.

Under this model, articles will no longer follow continuous page numbering within a volume. Instead, each article will begin on page 1 and receive a unique Article ID (eLocator), which will appear on every page and replace traditional page numbers in citations.

This approach ensures that articles receive their complete and final citation details immediately upon publication, improving accessibility, discoverability, and citation efficiency for authors and readers worldwide.

Here is the list of additional journals moving to the CP model.

#	Journal	Volume 2026	Issues in 2026
1	Current Pediatric Reviews	21	4
2	Recent Patents On Anti-Cancer Drug Discovery	20	5
3	Recent Advances In Inflammation and Allergy Drug Discovery	19	3
4	Current Green Chemistry	12	4
5	Recent Advances in Drug Delivery and Formulation	19	4
6	Current Biotechnology	19	4
7	Current Organocatalysis	12	4
8	Current Aging Science	18	3
9	Central Nervous System Agents In Medicinal Chemistry	25	4
10	MicroRNA	14	3
11	Current Medicinal Chemistry	17	4
12	Current Clinical Pharmacology	20	4
13	Recent Innovations In Chemical Engineering	18	4
14	Adolescent Psychiatry	16	3